First Albany Ups OSI Pharmaceuticals to 'Buy'

Analyst David Webber sees more upside potential if the drugmaker shows positive trial results for a lung cancer drug

First Albany upgraded OSI Pharmaceuticals (OSIP ) to buy from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.